Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells

Blood

Volumn 122, Issue 17, 2013, Pages 3086-3088

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Tanaka, Yuko ^a   Katagiri, Seiichiro ^a   Kitahara, Toshihiko ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CRK LIKE PROTEIN; HEAT SHOCK PROTEIN 90; HOMOHARRINGTONINE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PONATINIB; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AVIAN SARCOMA VIRUS; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; LETTER; LEUKEMIA CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HARRINGTONINES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDAZINES; SIGNAL TRANSDUCTION;

EID: 84891692250     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-494773     Document Type: Letter

References (9)

1. Breccia M, Alimena G. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. Cancer Lett. 2012;322(2):127-132.
2. Ernst T, Hochhaus A. Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol. 2012;39(1):58-66.
3. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367(22):2075-2088.
4. Cortes J, Lipton JH, Rea D, et al; Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573-2580.
5. Yu W, Mao L, Qian J, et al. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience. Ann Hematol. 2013;92(8):1091-1100.
6. Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489-498.
7. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5): 401-412.
8. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006; 5(3):723-731.
9. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS ONE. 2009;4(5): e5428.